Medical Linear Particle Accelerator Market Report 2025

This Medical Linear Particle Accelerator market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The medical linear particle accelerator market size has grown strongly in recent years. It will grow from $2.55 billion in 2024 to $2.69 billion in 2025 at a compound annual growth rate (CAGR) of 5.6%. The growth during the historic period can be attributed to factors such as improved access to healthcare, a growing demand for radiotherapy infrastructure, the rising need for proton therapy, the expansion of multimodal cancer treatments, and the increased adoption of robotic-assisted surgeries.

The medical linear particle accelerator market size is expected to see strong growth in the next few years. It will grow to $3.31 billion in 2029 at a compound annual growth rate (CAGR) of 5.3%. The projected growth during the forecast period can be attributed to factors such as the increasing demand for personalized medicine, greater adoption of affordable radiation therapy solutions, a rise in clinical trials, growing demand for minimally invasive surgery, and the wider use of targeted cancer therapies. Key trends expected to shape the forecast period include technological advancements in radiation therapy, the rise of telemedicine and remote radiotherapy planning, the integration of artificial intelligence (AI) and machine learning (ML), innovations in imaging modalities, and the incorporation of radiotherapy with digital health technologies.

In June 2023, Royal Philips, a health technology company based in the Netherlands, joined forces with Biotronik to broaden the range of cardiovascular devices available to users of Philips SymphonySuite, a leading solution designed for cardiovascular office-based labs (OBLs) and ambulatory surgery centers (ASCs). The collaboration integrates Philips SymphonySuite with Biotronik’s comprehensive selection of cardiac rhythm management and cardiovascular intervention products, thereby improving options for personalized patient care and supporting the shift towards out-of-hospital care settings. Biotronik, a US-based medical device company, specializes in providing products and services that aim to enhance the quality of life for patients with cardiovascular and endovascular conditions.

Leading companies in the medical linear particle accelerator market are focusing on creating advanced technologies, such as radiotherapy systems, to improve treatment accuracy and enhance patient outcomes in cancer therapy. Radiotherapy systems, including linear accelerators, use high-energy radiation to precisely target and treat tumors while minimizing damage to healthy surrounding tissue. For example, in May 2024, Elekta AB, a Swedish medical equipment manufacturer, introduced Elekta Evo, an AI-powered adaptive CT-linear accelerator designed to revolutionize cancer treatment. Featuring Iris, a high-definition AI-enhanced imaging system, Elekta Evo allows clinicians to clearly visualize treatment areas, ensuring precise targeting of tumors while safeguarding healthy tissue. The system also includes adaptive radiation therapy, enabling both online and offline modifications to treatment plans, thus offering personalized care tailored to each patient's specific needs.

In June 2024, Leo Cancer Care Inc., a UK-based company specializing in cancer treatment systems, teamed up with TibaRay Inc. to develop a next-generation upright linear accelerator. This collaboration marks a significant advancement in radiation therapy, combining TibaRay's cutting-edge linear accelerator technology with Leo Cancer Care's innovative upright patient positioning and imaging system. The goal of this partnership is to provide more effective and patient-focused cancer treatments. TibaRay Inc., based in the US, is known for manufacturing next-generation particle-accelerator-based systems for cancer treatment.

Major players in the medical linear particle accelerator market are Mitsubishi Electric Corporation, Siemens Healthineers AG, Toshiba Medical Systems Corporation, GE Healthcare, Shinva Medical Instrument Co Ltd, Sumitomo Heavy Industries Ltd, Neusoft Medical Systems Co Ltd, Elekta AB, Varex Imaging Corporation, Altair Engineering Inc, Accuray Incorporated, Brainlab, Nordion Inc., Ion Beam Applications S.A. (IBA), Hitachi Medical Corporation, ViewRay Technologies Inc., Laird Thermal Systems Inc., Panacea Medical Technologies Pvt Ltd, RadSource Technologies Inc., Xstrahl Limited, MedicalExpo S.A, ProTom International Inc., ASG superconductors, Galbino Technology Inc., Mevex Corporation, and TibaRay Inc.

North America was the largest region in the medical linear particle accelerator market in 2024. The regions covered in medical linear particle accelerator report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the medical linear particle accelerator market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

A medical linear particle accelerator (LINAC) is a device used in radiation therapy to treat cancer by delivering high-energy X-rays or electron beams to precisely target tumors while minimizing damage to surrounding healthy tissue. It uses microwave technology to accelerate electrons, generating radiation beams that are shaped to fit the tumor for effective treatment.

The primary types of medical linear particle accelerator products include dedicated and non-dedicated linear accelerators. A dedicated linear accelerator (linac) is specifically designed for delivering precise radiation therapy to treat cancer, minimizing harm to nearby healthy tissue. It supports various treatment techniques such as intensity-modulated radiation therapy, volumetric-modulated arc therapy, image-guided radiation therapy, stereotactic radiosurgery, and stereotactic body radiotherapy. These devices are used by hospitals, radiology centers, clinics, and other healthcare facilities.

The medical linear particle accelerator market research report is one of a series of new reports that provides medical linear particle accelerator market statistics, including the medical linear particle accelerator industry global market size, regional shares, competitors with the medical linear particle accelerator market share, detailed medical linear particle accelerator market segments, market trends, and opportunities, and any further data you may need to thrive in the medical linear particle accelerator industry. This medical linear particle accelerator market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The medical linear particle accelerator market consists of sales of quality assurance (QA) tools, treatment accessories, multileaf collimators (MLCs), patient immobilization systems, and beam-shaping devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.